Washington University School of Medicine

Digital Commons@Becker
2020-Current year OA Pubs

Open Access Publications

7-1-2022

Onasemnogene abeparvovec for presymptomatic infants with
three copies of SMN2 at risk for spinal muscular atrophy: The
Phase III SPR1NT trial
Kevin A Strauss
University of Massachusetts

Craig M Zaidman
Washington University School of Medicine in St. Louis

et al

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4
Part of the Medicine and Health Sciences Commons

Recommended Citation
Strauss, Kevin A; Zaidman, Craig M; and et al, "Onasemnogene abeparvovec for presymptomatic infants
with three copies of SMN2 at risk for spinal muscular atrophy: The Phase III SPR1NT trial." Nature
Medicine. 28, 7. 1390 - 1397. (2022).
https://digitalcommons.wustl.edu/oa_4/25

This Open Access Publication is brought to you for free and open access by the Open Access Publications at
Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized
administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Articles
https://doi.org/10.1038/s41591-022-01867-3

Onasemnogene abeparvovec for presymptomatic
infants with three copies of SMN2 at risk for spinal
muscular atrophy: the Phase III SPR1NT trial
Kevin A. Strauss 1,2,3 ✉, Michelle A. Farrar 4,5, Francesco Muntoni6,7, Kayoko Saito 8,
Jerry R. Mendell9,10, Laurent Servais 11,12, Hugh J. McMillan 13, Richard S. Finkel 14,15,
Kathryn J. Swoboda 16, Jennifer M. Kwon17, Craig M. Zaidman18, Claudia A. Chiriboga19,
Susan T. Iannaccone 20, Jena M. Krueger21, Julie A. Parsons22, Perry B. Shieh23, Sarah Kavanagh24,
Melissa Wigderson24, Sitra Tauscher-Wisniewski24, Bryan E. McGill 25 and Thomas A. Macek 24
Most children with biallelic SMN1 deletions and three SMN2 copies develop spinal muscular atrophy (SMA) type 2. SPR1NT
(NCT03505099), a Phase III, multicenter, single-arm trial, investigated the efficacy and safety of onasemnogene abeparvovec
for presymptomatic children with biallelic SMN1 mutations treated within six postnatal weeks. Of 15 children with three SMN2
copies treated before symptom onset, all stood independently before 24 months (P < 0.0001; 14 within normal developmental
window), and 14 walked independently (P < 0.0001; 11 within normal developmental window). All survived without permanent ventilation at 14 months; ten (67%) maintained body weight (≥3rd WHO percentile) without feeding support through
24 months; and none required nutritional or respiratory support. No serious adverse events were considered treatment-related
by the investigator. Onasemnogene abeparvovec was effective and well-tolerated for presymptomatic infants at risk of SMA
type 2, underscoring the urgency of early identification and intervention.

S

pinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease caused by deficiency of survival motor
neuron (SMN) protein resulting from biallelic deletions or
pathogenic variants of the SMN1 (survival motor neuron 1) gene.
SMN protein is essential for the development and survival of motor
neurons in the ventral spinal cord1. SMN2, a homologous gene
to SMN1, partially compensates for SMN1 loss by producing low
amounts of SMN protein2. SMN2 copy number correlates with SMA
onset and severity. Patients with three copies of SMN2 may develop
SMA types 1, 2 or 3, but the presence of three copies is 54% predictive of intermediate-severity SMA type 2 with onset between
7 months and 18 months of age, 15% predictive of type 1 and 31%
predictive of the milder type 3 phenotype3.
Untreated children with SMA type 2 experience relatively rapid
neuromuscular decline before 13 years of age, followed by more
gradual debilitation through adulthood4,5. Patients with SMA

type 2 achieve the ability to sit independently, but few stand and
none walk independently. With advancing age, nearly all patients
with SMA type 2 develop dysphagia, joint contractures, scoliosis, and restrictive lung disease, and some may lose the ability to
sit independently6–9. SMA type 3 causes less severe disability than
SMA type 2, with patients being able to stand and walk independently, although with increasing difficulty as they age. Patients
with SMA type 3 have later symptom onset and develop fewer
and less severe musculoskeletal, respiratory, and feeding problems7,8,10–12. Considerable heterogeneity within this clinical framework exists10,11. Observational studies of SMA type 2 and type 3
use continuous variables such as measures of motor performance,
upper limb strength and activity, pulmonary function, and compound motor action potential (CMAP)7,8,12–15. However, the slow
pace of clinical deterioration can obscure changes in these measures
over intervals typical of clinical trials8,12, and periods of 24 months
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or longer may be needed to assess the natural progression of SMA
type 2 or type 3.
Two approved therapies for SMA (nusinersen and risdiplam)
increase SMN protein production via modified splicing of SMN2
and require serial dosing16. A third approved disease-modifying
treatment, onasemnogene abeparvovec, is a gene replacement
therapy that delivers SMN cDNA using an adeno-associated virus-9
(AAV9) vector designed for one-time intravenous infusion17.
Because of early successes with SMA treatments, the United States
and several other countries have implemented widespread neonatal
screening for SMN1 deletions, enabling identification of children at
risk for SMA before symptom onset. This has critical implications
for therapeutic interventions18–20.
Single-center case series21–23, an observational cohort study24,
post-marketing data25,26 and the RESTORE patient registry27–29 demonstrate the safety and efficacy of onasemnogene abeparvovec for
symptomatic patients with SMA with three SMN2 copies. However,
few interventional studies have targeted children with three SMN2
copies who are at risk for SMA but have yet to demonstrate signs
of disease. This group is largely underrepresented in clinical trials.
Results from a Phase II study of nusinersen (NURTURE) indicate the potential of disease-modifying therapy for presymptomatic
children at risk for SMA type 2. Ten children with three copies of
SMN2 started nusinersen between 3 days and 42 days of age, before
symptom onset30. All children achieved independent sitting and
walking (most within the World Health Organization (WHO) normal reference interval), and none required respiratory intervention.
SPR1NT was the first Phase III study of onasemnogene abeparvovec for the treatment of presymptomatic infants at risk for SMA
types 1, 2 or 3. The SPR1NT trial focused on efficacy measures, such
as motor milestones, as they compared with normal developmental
benchmarks31 and the ability to survive and thrive without mechanical interventions. We also compared efficacy and exploratory measures with the Pediatric Neuromuscular Clinical Research (PNCR)
natural history population, which enrolled infants with SMA and
two or three copies of SMN214. A total of 29 SPR1NT participants
comprised 14 children with two copies of SMN2 and 15 with three
copies of SMN2. The former cohort is the subject of a companion
paper32. Here we focus on the 15 SPR1NT participants with three
copies of SMN2 (hereafter referred to as the three-copy cohort)
and provide important new efficacy and safety data about neonatal
AAV9 vector infusion in this population. Safety and efficacy data
from both cohorts have critical implications for newborn screening
programs and the clinical timing of therapeutic intervention.

Results

Screening and demographics. Of 44 newborns screened for
SPR1NT who had biallelic SMN1 deletions and two or three copies
of SMN2, 14 were excluded. The most common reasons for exclusion were clinical signs at screening or immediately before dosing
that were, in the opinion of the investigator, strongly suggestive of
SMA (n = 4) and peroneal nerve to tibialis anterior CMAP <2 mV
(n = 4) (Supplementary Table 1 and Supplementary Fig. 1). A total
of 15 infants (female, n = 9; 60%) with three SMN2 copies were
enrolled in SPR1NT. Children in the three-copy cohort were born
between 35 and 41 gestational weeks (median, 39.0) at a median
weight of 3.4 kg (range, 2.55–3.81) (Table 1). Ten children were born
at a gestational age less than 40 weeks, and one was born at a gestational age less than 37 weeks. None of the 15 infants had a c.859
G>C modifier variant, which is associated with a milder disease
course. Most children (n = 13; 87%) were diagnosed by newborn
screening. The 14 infants diagnosed after birth had a confirmed
molecular diagnosis at a median age of 8.0 days (range, 2–26).
At screening, all included infants demonstrated normal neuromuscular function and were able to swallow and breathe normally.
Median baseline peroneal CMAP was 4.10 mV (range, 2.7–7.0).
Nature Medicine | VOL 28 | July 2022 | 1390–1397 | www.nature.com/naturemedicine

Table 1 | Baseline characteristics of children with three copies
of SMN2
Baseline characteristics

All patients (n = 15)a

Age at dosing, daysb
Mean (s.d.)

28.7 (11.68)

Median (range)

32.0 (9–43)

Gestational age at birth, weeks
Mean (s.d.)

38.8 (1.47)

Median (range)

39.0 (35–41)

Weight at baseline, kg
Mean (s.d.)

4.1 (0.53)

Median (range)

4.1 (3.10–5.20)

Sex, n (%)
Male

6 (40)

Female

9 (60)

Race, n (%)
White

10 (67)

Asian

2 (13)

Other

2 (13)

American Indian or Alaska Native

1 (7)

Ethnicity, n (%)
Not Hispanic or Latino

13 (87)

Hispanic or Latino

2 (13)

Modality of SMA diagnosis, n (%)
Prenatal testing

1 (7)

Newborn screening

13 (87)

Other

1 (7)

Age at SMA diagnosis, daysc
n (number of children diagnosed after birth)

14

Mean (s.d.)

9.9 (7.69)

Median (range)

8.0 (2–26)

ITT population, n = 6 males and n = 9 females; mean (s.d.) age at dosing, 28.7 (11.68) days. bAge
at dosing = (dose date − date of birth + 1). cAge at SMA diagnosis = (SMA diagnosis date − date of
birth + 1). Only calculated for patients who were diagnosed after birth.
a

All 15 infants enrolled in the three-copy cohort received the
onasemnogene abeparvovec infusion at a median age of 32 days
(range, 9–43), with a median baseline weight of 4.1 kg (range,
3.1–5.2). Infusion interruption occurred in one child because of a
pump malfunction, but this child still received all of the intended
dose. All children completed the study and were included in the
intention-to-treat (ITT) population.
Primary and secondary motor milestone endpoints. All 15 (100%)
children achieved the primary endpoint of independent standing,
confirmed by independent video review, for at least 3 seconds at any
visit up to 24 months of age. Children achieved this motor milestone
at a median age of 377 days (range, 284–549), and 14 of 15 (93%) did
so within the normal WHO developmental window of ≤514 days
(99th percentile) (Fig. 1). All children maintained this motor milestone at the 24-month study visit. For comparison, only 19 of 81
(24%) patients with SMA in the PNCR natural history population
achieved independent standing (P < 0.0001)14.
Fourteen (93%) children in the three-copy cohort walked independently for at least five steps at any visit up to 24 months of age,
compared to 17 of 81 patients (21%) in the PNCR population
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Fig. 1 | Video-confirmed developmental motor milestones for children with three copies of SMN2. Months calculated as days / 30. Only the first
observed instance of a milestone is included in this figure. Shaded areas indicate the World Health Organization Multicentre Growth Reference Study
(WHO-MGRS) windows for normal development; the 99th percentile (that is, upper bound of normal development) of sits without support is 279 days,
stands alone is 514 days, and walks alone is 534 days. aBayley Scales gross motor subtest item #26: child sits alone without support for at least 30 seconds.
b
Bayley Scales gross motor subtest item #40: child stands alone. Child stands alone for at least 3 seconds after you release his or her hands. cBayley Scales
gross motor subtest item #43: child walks alone. Child takes at least five steps independently, displaying coordination and balance. n = 6 males and n = 9
females; mean (s.d.) age at dosing, 28.7 (11.68) days.

(P < 0.0001)14. The median age of independent walking was
422.0 days (range, 362–563), and 11 (73%) children achieved this
motor milestone within the WHO normal developmental window
of ≤534 days of age. Notably, one additional child in the three-copy
cohort was observed walking during the 24-month study visit (conducted via video call) by the clinical evaluator, but video was not
recorded. Therefore, per the study protocol, the child was judged
not to have achieved this motor milestone in the absence of an independent video review. A detailed summary of motor milestones is
included in Supplementary Table 2.
Exploratory functional endpoints. All 15 (100%) children in the
three-copy cohort were alive and free from permanent ventilation at
14 months of age, and ventilator-free survival remained 100% at the
end of the study. In fact, no child required mechanical respiratory
support of any kind (for example, cough-assist, bilevel positive airway pressure, or invasive ventilatory support) throughout the duration of the trial. Ten of 15 (67%) children were at or above the 3rd
reference percentile for weight at all study visits, and all children were
at or above this percentile at the end of the study (Fig. 2). In addition,
no child required a feeding tube at any point during the study.

All 15 children were adequately assessed using the BSID, although
one (7%) child missed the baseline assessment, precluding calculation of a change from baseline. Incremental gains in gross and
fine motor raw scores generally tracked with the normal reference
population (Fig. 3 and Supplementary Table 3). Raw scores were
converted to scaled scores with a normative mean of 10 and a standard deviation (s.d.) of 3, such that scaled scores of 4–16 capture the
3rd to 97th percentile range for normal motor development. All 15
(100%) children in the three-copy cohort achieved a scaled score
of ≥4 (within 2 s.d. of the reference mean) on both the gross motor
and fine motor subtests during at least one post-baseline visit. For
each scheduled visit, most assessed children (78–100%) met the
criteria at that visit. At the 24-month visit, all ten (100%) children
who were assessed achieved a scaled score of ≥4, with the median
gross motor scaled score of 9 (range, 5–12), close to the normative
population mean (Supplementary Table 4). Gains in motor function
were paralleled by electrophysiologic evidence of preserved motor
nerve integrity. The median maximum peroneal CMAP recorded
at any post-infusion visit was 6.00 mV (range, 4.2–8.5), representing a median increase from baseline of 1.80 mV (range, −0.6 to 5.0)
(Supplementary Table 5).

Exploratory motor endpoints. The Bayley Scales of Infant and
Toddler Development (BSID) provide a more granular appraisal of
development compared with an age-matched reference population33.

Safety observations. To attenuate the inflammatory response to
AAV9, all 15 children commenced oral prednisolone 1 day before
onasemnogene abeparvovec infusion and completed a median of

1392

Nature Medicine | VOL 28 | July 2022 | 1390–1397 | www.nature.com/naturemedicine

Articles

Nature Medicine
Females

20
18

Child 1

16

Child 2
14

Child 3
Child 4

Weight (kg)

12

Child 6
Child 7

10

Child 9
Child 12

8

Child 14
6
4
2
0

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Age (months)
Males

20

18

16
Child 5
Child 8

14

Child 10
Child 11

Weight (kg)

12

Child 13
10

Child 15

8

6

4

2

0

0

1

2

3

4

5

6

7

8

9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Age (months)

Fig. 2 | Growth charts for children with three copies of SMN2. Ten (67%) children achieved the ability to maintain weight at or above the WHO 3rd
percentile without the need for non-oral/mechanical feeding support at all visits up to 24 months of age. The ability to maintain weight at or above the 3rd
percentile without the need for non-oral/mechanical feeding support was defined by meeting both of the following criteria at all visits: (1) does not receive
nutrition through mechanical support (that is, feeding tube) and (2) maintains weight (≥3rd percentile for age and sex as defined by WHO guidelines)
consistent with the patient’s age at the assessment. The gray shading represents WHO growth standards for the 3rd through 97th percentiles. n = 6 males
and n = 9 females; mean (s.d.) age at dosing, 28.7 (11.68) days.

63 days (range, 49–321) of therapy. A total of 166 treatment-emergent
adverse events (TEAEs) were reported (Supplementary Tables 6 and
7). Each child experienced at least one TEAE, and three (20%) had
Nature Medicine | VOL 28 | July 2022 | 1390–1397 | www.nature.com/naturemedicine

a TEAE reported as serious. Eight of 15 (53%) children had a TEAE
considered by the investigator to be related to the study treatment,
but none was serious.
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Fig. 3 | Bayley scales fine motor and gross motor raw scores. Improvements were observed in all children for both gross (a) and fine (b) subtests of the
Bayley Scales of Infant and Toddler Development after onasemnogene abeparvovec infusion and up to 24 months of age. The gray shading represents
Bayley-III gross and fine motor normal ranges (±2 s.d.). n = 6 males and n = 9 females; mean (s.d.) age at dosing, 28.7 (11.68) days.

Transient decreases in platelets have been observed after administration of onasemnogene abeparvovec34. Preclinical studies in
animal models have reported cardiac thrombi and dorsal root ganglia toxicities, but these have not been observed clinically25. On the
basis of these data, the study sponsor (Novartis Gene Therapies)
identified five specific categories of adverse events (AEs) of special
interest (AESI): hepatotoxicity, thrombocytopenia, cardiac toxicity,
thrombotic microangiopathy (TMA), and sensory abnormalities
suggestive of dorsal root ganglionopathy (Table 2). AESIs were identified using specific terms in standardized Medical Dictionary for
Regulatory Activities (MedDRA) coding dictionary queries related
to these categories (see Methods for further details).
Thirteen hepatotoxicity AESIs occurred in four of 15 (27%) children. All events were mild or moderate, except for a single Grade 3
event of increased alanine aminotransferase (five or more times the
1394

upper limit of normal). The investigator considered all events as related
to treatment. All hepatotoxicity events resolved, including the Grade
3 event that resolved with augmented prednisolone (Supplementary
Table 8). No clinically observed events of jaundice or hepatic
encephalopathy were reported. Three thrombocytopenia-related
events occurred in two of 15 (13%) children. None of the events
was associated with decreased platelet counts. These events were
mild or moderate, considered unrelated to treatment, and resolved
without sequelae (Supplementary Table 9). To assess cardiac toxicity, creatinine phosphokinase (CK)-MB was initially measured but
was changed, mid-study, to the more reliable cardiac tissue marker
troponin I. CK-MB was not assessed after this change. Eight children had both baseline and post-baseline CK-MB values, and five
children had both baseline and post-baseline troponin I values. Four
AEs of elevated cardiac enzymes were reported in three children: one
Nature Medicine | VOL 28 | July 2022 | 1390–1397 | www.nature.com/naturemedicine
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Table 2 | TEAEs of special interest in children with three copies
of SMN2
Category of AESI

n = 15a

Preferred term

n (%)

Hepatotoxicity
Any TEAE

4 (27)

Aspartate aminotransferase increased

4 (27)

Alanine aminotransferase increased

3 (20)

Blood alkaline phosphatase increased

1 (7)

Gamma-glutamyltransferase increased

1 (7)

Thrombocytopenia
Any TEAE

2 (13)

Hematemesis

1 (7)

Hematochezia

1 (7)

Contusion

1 (7)

Cardiac adverse events
Any TEAE

3 (20)

Blood creatine phosphokinase MB increased

2 (13)

Troponin increased

2 (13)

Thrombotic microangiopathy
Any TEAE
Thrombocytopenia

0 (0)
0 (0)

Sensory abnormalities suggestive of dorsal root ganglionopathy
Any TEAE

1 (7)

Areflexia

1 (7)

Safety population: n = 6 males and n = 9 females; mean (s.d.) age at dosing, 28.7 (11.68) days.

a

had elevated CK-MB and troponin I; one had an isolated elevation of
CK-MB; and one had an isolated elevation of troponin I (Table 2). All
events were mild or moderate and considered possibly or probably
related to treatment. At the end of the study, serum CK-MB remained
elevated in one child, and the two cardiac AESIs resolved without
sequelae in the other two children (Supplementary Table 10). No
TMA events were reported during the study. One of 15 (7%) children had two AESIs (areflexia), which could potentially be related to
dorsal root ganglionopathy. However, these events were mild and not
related to treatment. One event resolved and one was ongoing at the
last study visit (Supplementary Table 11).

Discussion

SPR1NT demonstrates that a single intravenous dose of onasemnogene abeparvovec promotes motor development for presymptomatic neonates with biallelic deletions of SMN1 and three copies of
SMN2 who are primarily at risk for SMA type 2. Without treatment,
most of these children would achieve motor milestones no more
advanced than independent sitting, whereas those treated with
onasemnogene abeparvovec displayed patterns of motor development indistinguishable from healthy children without SMA.
Specifically, all but one of the 15 children achieved independent
walking (the remaining child stood independently), and all had
BSID gross and fine motor scores similar to neurologically normal peers. Exceptional motor and functional outcomes were also
observed for children in the two-copy cohort of SPR1NT32.
Remarkably, no child in SPR1NT required mechanical feeding
or respiratory support, indicating that presymptomatic gene therapy has the potential to prevent some musculoskeletal, pulmonary,
and growth complications characteristic of classic SMA type 2. This
Nature Medicine | VOL 28 | July 2022 | 1390–1397 | www.nature.com/naturemedicine

represents a profound shift in the early course of illness to a much
milder SMA phenotype or possibly even to normal motor development. Given the durability of benefit observed in the follow-up
study of the Phase I START trial35, and the fact that motor neurons
are non-dividing cells, we are optimistic that one-time treatment
with onasemnogene abeparvovec will add years of independent
mobility, intact bulbar function, and good health-related quality of
life for children in the three-copy cohort.
Table 3 places SPR1NT in the context of three other clinical trials: STR1VE-US36, STR1VE-EU37 and a Phase II study of infants
with two or three copies of SMN2 treated with nusinersen before
symptom onset (NURTURE)29. A presymptomatic study with risdiplam (RAINBOWFISH) is still in progress38. Overall, Table 3
highlights the importance of treatment timing (that is, before the
onset of clinical symptoms) as a potentially important determinant
of outcome, but noteworthy differences in the designs of these trials prevent direct comparisons between them. Primary endpoints
of the percentage of children who achieved the independent standing (BSID item #40) and independent walking (BSID item #43)
motor milestones were included for the SPR1NT three-copy cohort
versus only independent sitting (using WHO and Hammersmith
Infant Neurological Examination section 2 criteria) in NURTURE.
Eligibility criteria also differed, including ability to tolerate thin liquids, peroneal CMAP ≥2 mV, and presymptomatic SMA in SPR1NT
versus ulnar CMAP ≥1 mV, absence of hypoxia, and no clinical
signs or symptoms suggestive of SMA in NURTURE. Motor milestone achievement in both the two-copy and three-copy cohorts of
SPR1NT is also distinguished from other studies by its stringency,
requiring video confirmation by an independent observer in both
the two-copy and three-copy cohorts. In NURTURE, however,
parents or caregivers reported motor milestone achievement, and
confirmation followed at the next site visit, and age at milestone
achievement was reported by parents, caregivers, or site investigators. Regardless of these differences, children with few or no clinical signs of SMA who receive treatment appear to achieve more
advanced developmental milestones than children who receive
treatment after the clinical onset of disease.
We also observed that presymptomatic neonatal treatment with
intravenous onasemnogene abeparvovec demonstrated a favorable
safety profile, and no new or unexpected safety concerns were identified with treatment administration between 9 days and 43 days of
age. Although all children had at least one AE, few experienced serious AEs, and no treatment-related serious AEs or deaths related to
treatment were reported. Furthermore, AESIs were generally mild
or moderate and resolved. Transient elevations of liver enzymes
were asymptomatic and generally mild. Transient changes in platelet counts were observed, but no child had a platelet count below
75,000 cells per µl. All thrombocytopenia-related AESIs were mild
to moderate, and all resolved. Asymptomatic and mild elevations
of cardiac enzymes occurred in a minority of children but were
not associated with signs of ventricular dysfunction or thrombosis.
TMA, which presents clinically as hemolytic anemia, thrombocytopenia, and acute kidney injury, has been identified as a risk for
onasemnogene abeparvovec based on post-marketing safety surveillance39, but no cases of TMA occurred in SPR1NT. A single case
of areflexia persisted at the time of study conclusion, and, although
areflexia is a component of the clinical picture of sensory ganglionopathy, other clinical symptoms of this condition were absent,
increasing the likelihood that this AESI was a complication of one
child’s underlying SMA diagnosis. The possibility that the favorable
safety profile of onasemnogene abeparvovec observed in SPR1NT
relates to maturational differences in the immune response is
discussed briefly in the companion manuscript32. Limitations of
SPR1NT are the relatively small number of participants, the use
of an external comparator group, and the exclusion of participants
with CMAP <2 mV at screening.
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Table 3 | Summary of SPR1NT results and other SMA studies and cohortsa
Onasemnogene abeparvovec
Symptomatic patients
PNCR

14

Nusinersen

Presymptomatic children

Presymptomatic children

STR1VE-US

STR1VE-EU

SPR1NT,
two-copy
cohort

SPR1NT,
three-copy
cohort

NURTURE,b
NURTURE,b
two-copy cohort30 three-copy
cohort30

32

14

15

15

36

37

Intention-to-treat
population, n

23

22

10

SMN2 copies

2

2

2

2

3

2

3

Median (range) age at
diagnosis, days

N/A

67 (56–126)c

76 (26–156)

8 (1–14)

8 (2–26)

N/A

N/A

Median (range) age at
infusion, days

N/A

105 (15–177)

123 (54–180)

21 (8–34)

32 (9–43)

19 (8–41)

23 (3–42)

Baseline median (range)
CHOP INTEND

32.5 (31–33)d

33.5 (18–52)

28.0 (14–55)

48.5 (28–57) N/A

45.0 (25–60)

53.5 (40–60)

Baseline median (range)
CMAP amplitude, mVe

0.3 (0.04–1.1)

N/A

N/A

3.9 (2.1–6.1)

4.1 (2.7–7.0)

3.2 (1.1–9.7)

4.0 (0.2–7.0)

Sitting independently by
18 months, n (%)f

0

14 (64)

14 (44)

14 (100)

N/A

N/A

N/A

Sitting independently by
24 months of age, n (%)f

0

N/A

N/A

N/A

14 (93)

15 (100)

10 (100)

Standing independently by
18 months of age, n (%)f

0

1 (5)

1 (3)

11 (79)

N/A

N/A

N/A

Standing independently by
24 months of age, n (%)f

0

N/A

N/A

N/A

15 (100)

9 (60)

10 (100)

Walking independently by
18 months of age, n (%)f

0

1 (5)

1 (3)

9 (64)

N/A

N/A

N/A

Walking independently by
24 months of age, n (%)f

0

N/A

N/A

N/A

14 (93)

9 (60)

10 (100)

Alive without permanent
ventilation at 18 months of
age, n (%)f

6 (26)g

20 (91)

31 (97)

14 (100)

15 (100)

15 (100)

10 (100)

HINE-2, Hammersmith Infant Neurological Examination section 2; N/A, not available. aThere are no published head-to-head studies of onasemnogene abeparvovec and nusinersen. Differences in trial design,
including primary endpoints, how endpoints were measured, and eligibility criteria, make direct comparison of results from these studies infeasible. The PNCR measured CHOP INTEND; NURTURE measured
WHO and HINE-2 criteria; and STR1VE-US and STR1VE-EU measured WHO criteria and CHOP INTEND. bNURTURE results represent interim analysis at data cut of 29 March 2019. At the time of this analysis,
the median age of the infants was 34.8 months (range, 25.7–45.4)26. cMedian (range) is reported as the interquartile range. dValue obtained for patients with symptom onset <3 months of age, including seven
patients with two SMN2 copies and one patient with three SMN2 copies eUlnar CMAP amplitude recorded from the abductor digiti minimi muscle at baseline for the PNCR and NURTURE studies and peroneal
CMAP amplitude recorded from the tibialis anterior muscle for SPR1NT. fMilestones were evaluated over different observation periods between studies and included 18 months for STR1VE-US, STR1VE-EU, and
SPR1NT two-copy cohort; 24 months for the SPR1NT three-copy cohort; and a median follow-up time of 35 months for NURTURE. gSurvival without permanent ventilation at 14 months.

Two decades ago, the Human Genome Project promised new
diagnostics and therapeutics based on the identification of underlying
genetic mechanisms of disease40. Ultimately, genomics research aimed
to change medical practice from a reactive stance, in which presenting
signs and symptoms of disease prompt treatment, to a proactive one,
in which deep understanding of underlying vulnerabilities within the
genome allows providers to anticipate future health risks and apply
precise interventions that keep people healthy. The goal was to find
the right treatment for the right patient at the right time and, thereby,
prevent disease and disability41,42. This goal may soon be realized for
children with SMA, with the discovery of its molecular basis, effective
therapies, and the optimal timing for intervention.
For all forms of SMA, genomic medicine appears to be entering
the realms of public health and preventive pediatrics. Children at
risk for SMA types 2 or 3 who were treated once with onasemnogene
abeparvovec before 6 weeks of age, before the onset of symptoms,
demonstrated normal or nearly normal patterns of growth and neuromuscular development in this study. Our findings underscore the
urgency of early identification of children at risk for SMA by newborn screening, followed by timely treatment to prevent death and
disability. This has critical implications for the implementation of
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universal newborn screening for SMN1 deletions, discussed more
fully in the companion two-copy manuscript32.
In the past 2 decades, advances in medical genetics have propelled the development of new therapies for monogenic disorders
such as SMA, increased understanding of their underlying pathophysiology, and permitted development of new genetic diagnostic
tools42–44. However, treating individuals who demonstrate no symptoms of disease remains controversial. SMA offers an example of
what can be achieved when newborn screening identifies at-risk
infants who can potentially be spared the consequences of severe,
debilitating weakness. Children with three copies of SMN2 have a
greater likelihood of developing SMA type 2 or type 3, but SPR1NT
demonstrates that treating three-copy children before the appearance of SMA symptoms essentially allows them to grow and develop
as normal children. This represents a remarkable evolution in the
standard of care for SMA: from a reactive to a proactive paradigm,
from a focus on patients who survive to children who thrive.
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Methods

Study design. SPR1NT was an open-label, single-arm, Phase III study conducted
at 16 sites in six countries (Australia, Belgium, Canada, Japan, the United Kingdom
and the United States). The study was conducted in accordance with the Declaration
of Helsinki, International Council for Harmonisation/Good Clinical Practice
guidelines and applicable regulatory requirements (for example, those relating to
informed consent and the protection of human patients in biomedical research).
The study was approved by institutional review boards (IRBs) at all participating
institutions (Advarra Center for IRB Intelligence, Nationwide Children’s Hospital;
UCLA Medical Center IRB #3, David Geffen School of Medicine at the University
of California, Los Angeles; Nemours Office of Human Subjects Protection, Nemours
Children’s Clinic; Columbia University Medical Center IRB, Columbia University
Medical Center; Advarra Center for IRB Intelligence, Massachusetts General
Hospital; Children’s Hospital of Eastern Ontario Research Ethics Board, Children’s
Hospital of Eastern Ontario; Sydney Children’s Hospitals Network Human Research
Ethics Committee, Sydney Children’s Hospital; University of Pennsylvania IRB,
Clinic for Special Children; Tokyo Women’s Medical University IRB, Tokyo
Women’s Medical University Hospital; The Dubowitz Neuromuscular Centre IRB,
University College London; and The Neuromuscular Center of Liège, CHU &
University of Liège), and written informed consent was obtained from parents or
legal guardians of enrolled patients.
Patients. The study included presymptomatic children who had SMA genetically
defined by biallelic deletions of SMN1 with either two or three copies of SMN2
expected to develop SMA type 1 or SMA types 2 or 3, respectively. Children were
enrolled in two separate cohorts according to the number of SMN2 copies present.
Children with SMN1 point mutations (that is, pathogenic variants) or the SMN2
gene modifier variant (c.859 G>C) could enroll, but those with the SMN2 gene
modifier variant would not be included in the ITT population. Efficacy and safety
findings for children with three SMN2 copies are reported. The study planned
to enroll at least 12 children with three copies of SMN2 who met the ITT criteria
and were ≤6 weeks of age at the time of gene replacement therapy (Day 1). Full
eligibility criteria are described in the Supplementary Material.
The Coronavirus Disease 2019 (COVID-19) pandemic did not affect retention.
No participant withdrew from SPR1NT or was lost to follow-up because of the
COVID-19 pandemic. However, some scheduled study visits and assessments were
delayed or cancelled because of restrictions caused by the COVID-19 pandemic.
Procedures. All children were admitted into the hospital for pretreatment baseline
procedures 1 day before infusion. For all assessments, baseline was defined as the
last assessment conducted before dosing. Onasemnogene abeparvovec (1.1 × 1014
vector genomes per kilogram (vg kg−1)) was administered as a single intravenous
infusion (given over approximately 60 minutes) between 18 September 2018
and 9 July 2019. Safety monitoring was conducted while the children remained
in the hospital for a minimum of 24 hours after infusion. All children received
prophylactic prednisolone (initially 1 mg/kg/day, increased to 2 mg/kg/day
following a protocol amendment in May 2019) beginning 24 hours before infusion
and for 48 hours after infusion, after which the dosage was 1 mg/kg/day during
a minimum of 30 days. Thereafter, prednisolone was tapered according to a
standard algorithm and based on a requirement that gamma-glutamyltransferase,
alanine aminotransferase, and aspartate aminotransferase values were below the
threshold of twice the upper limit of normal. Investigators were permitted to use
other glucocorticosteroids in place of prednisolone, change the daily prednisolone
dosage, and alter the taper schedule according to their clinical judgment.
Outpatient follow-up assessments were conducted on Days 7, 14, 21, 30, 44,
51 (in Japan only), 60, and 72 post-dose, and then at 3 months of age and every
3 months thereafter through 24 months of age (that is, the end-of-study visit). All
eligible children were invited to enroll in an ongoing long-term follow-up study
(LT-002, NCT04042025).
Outcomes. The primary efficacy endpoint was the ability to stand independently
for ≥3 seconds at any visit up to 24 months of age, as stipulated by item #40
from the gross motor subtest of the BSID. The secondary efficacy endpoint
was the ability to walk alone for at least five steps at any visit up to 24 months
of age, as stipulated by item #43 of the BSID33. Exploratory endpoints were
survival at 14 months of age, defined as the avoidance of death or requirement of
permanent ventilation (tracheostomy or ≥16 hours of daily respiratory assistance
for ≥14 consecutive days in the absence of an acute reversible illness, excluding
perioperative ventilation) and the ability to maintain body weight at or above the
3rd percentile without the need for feeding support at any visit up to 24 months
of age. Other exploratory endpoints included achievement of motor milestones
and changes from baseline as assessed by World Health Organization Multicentre
Growth Reference Study (WHO-MGRS) and BSID version 3 gross motor criteria,
Children’s Hospital of Pennsylvania Infant Test of Neuromuscular Disorders
(CHOP INTEND) scores, and scores on the BSID gross and fine motor subtests.
Videos demonstrating developmental milestones meeting WHO and BSID
criteria (as part of clinical evaluation at study visits or submitted by parent(s)/legal
guardian(s) at any time during the study) were reviewed by an independent,
central reviewer for unbiased assessment and confirmation of developmental
milestone achievement.
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Safety monitoring. Safety was assessed by monitoring for AEs, physical
examinations, pulmonary examinations, vital signs, weight and length
measurements, 12-lead electrocardiograms, 24-hour Holter monitoring,
echocardiograms, swallowing tests, laboratory assessments, and photographs of
the infusion site. Pulmonary examinations were performed by a pulmonologist
or appropriate individual according to standard institutional practice. All AEs
were recorded and classified in accordance with the Common Terminology
Criteria for Adverse Events (version 4.03) (https://www.eortc.be/services/doc/ctc/
ctcae_4.03_2010-06-14_quickreference_5×7.pdf).
Statistical analysis. Data were analyzed using SAS version 9.4 software
(SAS Institute). Primary and secondary efficacy analyses were performed for
participants with biallelic SMN1 deletions and three copies of SMN2 without the
SMN2 gene modifier variant (c.859 G>C), which is associated with a less severe
clinical course45, who were included in the ITT population. Primary and secondary
outcomes were compared with a cohort of population-matched patients from
the PNCR natural history data set (all patients with any type of SMA and three
copies of SMN2; the SMN2 modifier mutation (c.859 G>C) was not assessed in the
PNCR study cohort)14. This study was designed to have >90% power with α = 0.05
to detect a significant difference in independent standing using a two-sided
Fisher exact test on a sample size of ≥12 children into the ITT population as well
as assumptions based on a matched PNCR dataset14 and START study data17.
Formal testing for the primary and secondary efficacy endpoints was performed
using a hierarchical approach to protect against Type I error as follows. First, the
primary motor endpoint of independent standing for ≥3 seconds was assessed. If
the analysis of the primary endpoint was determined to be statistically significant
(P < 0.05), then formal testing of the secondary motor endpoint, walking
independently, was conducted.
The safety population included all children who received onasemnogene
abeparvovec. Safety was evaluated through reported AEs as well as objective data
variables, including vital signs, physical examinations, and laboratory studies.
These data are presented in a descriptive fashion. AEs were coded using an
industry standardized MedDRA coding dictionary (version 23.0), and AESIs were
classified through specific predefined MedDRA terms (Supplementary Table 12).
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.

Data availability

A redacted version of the SPR1NT study protocol and a redacted version of the
statistical analysis plan are available at ClinicalTrials.gov (NCT03505099). Novartis
is committed to sharing clinical trial data with external researchers and has been
doing so voluntarily since 2014.
Novartis is committed to sharing, upon requests from qualified external researchers
and subsequent approval by an independent review panel based upon scientific
merit, anonymized patient-level and study-level clinical trial data and redacted
clinical study reports for medicines and indications approved in the United States
and Europe after the respective study is accepted for publication. All data provided
are anonymized to respect the privacy of patients who have participated in the trial,
in line with applicable laws and regulations. This trial data availability is according
to the criteria and process described on www.clinicalstudydatarequest.com.
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Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.

A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient)
AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.

For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Our web collection on statistics for biologists contains articles on many of the points above.

Software and code
Policy information about availability of computer code
Data collection

No software was used for data collection.

Data analysis

Data were analyzed using SAS Version 9.4 software (SAS Institute).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and
reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

A redacted version of the SPR1NT study protocol and a redacted version of the statistical analysis plan are available at ClinicalTrials.gov (NCT03505099). Novartis is
committed to sharing clinical trial data with external researchers and has been doing so voluntarily since 2014. Novartis is committed to sharing, upon requests
from qualified external researchers and subsequent approval by an independent review panel based upon scientific merit, anonymized patient-level and study-level
clinical trial data, and redacted clinical study reports, for medicines and indications approved in the United States and Europe after the respective study is accepted
for publication. All data provided are anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
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Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size

This study was designed to have >90% power with α = 0.05 to detect a significant difference in independent standing using a two-sided Fisher
exact test on a sample size of ≥12 children into the ITT population as well as assumptions based on a matched PNCR data set and START study
data. Formal testing for the primary and secondary efficacy endpoints was performed using a hierarchical approach to protect against Type I
error as follows. First, the primary motor endpoint of independent standing ≥3 seconds was assessed. If the analysis of the primary endpoint
was determined to be statistically significant (P<0.05), then formal testing of the secondary motor endpoint, walking independently, was
conducted.

Data exclusions

No data were excluded from the analyses.

Replication

This was an open-label single-arm study that included efficacy and safety assessments for each patient. Assessments were repeated for each
patient at the relevant follow-up visit as per protocol, but were not replicated for each patient at each time point.

Randomization

This was an open-label single-arm study. Patients were not randomized to study groups.

Blinding

This study was an open-label design and no blinding was used.
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Methods

n/a Involved in the study

n/a Involved in the study
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Human research participants
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Human research participants
Policy information about studies involving human research participants
Population characteristics

Fifteen presymptomatic infants with genetically confirmed SMA and three SMN2 copies (60% female) were enrolled and
treated with onasemnogene abeparvovec. Children in the three-copy cohort were born between 35 and 41 (median 39)
gestational weeks, with a median weight of 3.4 kg (range, 2.55–3.81 kg). Ten children were born prior to a gestational age at
birth of <40 weeks (less than full-term gestation), and one patient had a gestational age of <37 weeks. All 15 children had
biallelic SMN1 deletions and three SMN2 copies (no c.859C>G modifier variants) detected presymptomatically through either
prenatal screening (n = 1, 7%) or newborn screening (n = 13, 87%). The 13 children referred by newborn screening had a
confirmed molecular diagnosis at median age 8 days (range, 2–26 days).
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Infants eligible for enrollment in the three-copy cohort of SPR1NT must have been genetically diagnosed with
presymptomatic spinal muscular atrophy (SMA) with three copies of SMN2, ≤6 weeks (≤42 days) of age at the time of
treatment, were able to tolerate thin liquids as demonstrated through a formal bedside swallowing test, had a baseline
peroneal nerve to tibialis anterior compound muscle action potential (CMAP) value of ≥2 mV, were at a gestational age of 35
to 42 weeks, were up-to-date on childhood vaccinations that include palivizumab prophylaxis (also known as Synagis®) to
prevent respiratory syncytial virus infections, able and willing to follow the Consensus Statement for Standard of Care in
Spinal Muscular Atrophy and parent(s)/legal guardian(s) willing and able to complete the informed consent process and
comply with study procedures and visit schedule. Genetic diagnoses had to be obtained from an acceptable newborn or
prenatal screening test method.
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Recruitment

SMA is a rare disease, and the study was conducted at specialized tertiary care centers. There were no active recruitment
efforts that would create bias.

Ethics oversight

The study was approved by institutional review boards (IRBs) at all participating institutions (Advarra Center for IRB
Intelligence, Nationwide Children’s Hospital; UCLA Medical Center IRB #3, David Geffen School of Medicine at University of
California Los Angeles; Nemours Office of Human Subjects Protection, Nemours Children’s Clinic; Columbia University
Medical Center IRB, Columbia University Medical Center; Advarra Center for IRB Intelligence, Massachusetts General
Hospital; Children’s Hospital of Eastern Ontario Research Ethics Board, Children’s Hospital of Eastern Ontario; Sydney
Children’s Hospitals Network Human Research Ethics Committee, Sydney Children’s Hospital; University of Pennsylvania IRB,
Clinic for Special Children; Tokyo Women’s Medical University IRB, Tokyo Women’s Medical University Hospital; The
Dubowitz Neuromuscular Centre IRB, University College London; The Neuromuscular Center of Liège, CHU & University of
Liège), and written informed consent was obtained from parents or legal guardians of enrolled patients.
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Infants eligible for enrollment in the three-copy cohort of SPR1NT must have been genetically diagnosed with
presymptomatic spinal muscular atrophy (SMA) with three copies of SMN2, ≤6 weeks (≤42 days) of age at the time of
treatment, were able to tolerate thin liquids as demonstrated through a formal bedside swallowing test, had a baseline
peroneal nerve to tibialis anterior compound muscle action potential (CMAP) value of ≥2 mV, were at a gestational age of 35
to 42 weeks, were up-to-date on childhood vaccinations that include palivizumab prophylaxis (also known as Synagis®) to
prevent respiratory syncytial virus infections, able and willing to follow the Consensus Statement for Standard of Care in
Spinal Muscular Atrophy and parent(s)/legal guardian(s) willing and able to complete the informed consent process and
comply with study procedures and visit schedule. Genetic diagnoses had to be obtained from an acceptable newborn or
prenatal screening test method.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data
Policy information about clinical studies
All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Clinical trial registration ClinicalTrials.gov NCT03505099, registration date April 23, 2018.
Study protocol

A redacted version of the SPR1NT study protocol and a redacted version of the statistical analysis plan are available at
ClinicalTrials.gov.

Data collection

Data collection began between September 18, 2018, and July 9, 2019, at the time of onasemnogene abeparvovec infusion, and the
patients were followed for 24 months. Data collection was undertaken at 16 sites in six countries (Australia, Belgium, Canada, Japan,
United Kingdom, and the United States of America).

Outcomes

The primary efficacy endpoint was the ability to stand independently for ≥3 seconds at any visit up to 24 months of age, as stipulated
by item #40 from the gross motor subtest of the BSID. The secondary efficacy endpoint was the ability to walk alone for at least five
steps at any visit up to 24 months of age, as stipulated by item #43 of the BSID.30 Exploratory endpoints were survival at 14 months
of age, defined as the avoidance of death or requirement of permanent ventilation (tracheostomy or ≥16 hours daily respiratory
assistance for ≥14 consecutive days in the absence of an acute reversible illness, excluding perioperative ventilation) and the ability
to maintain body weight at or above the 3rd percentile without the need for feeding support at any visit up to 24 months of age.
Other exploratory endpoints included achievement of motor milestones and changes from baseline as assessed by World Health
Organization Multicentre Growth Reference Study (WHO-MGRS) and BSID Version 3 Gross Motor criteria, CHOP INTEND scores, and
scores on the BSID gross and fine motor subtests. Videos demonstrating developmental milestones meeting WHO and BSID criteria
(as part of clinical evaluation at study visits or submitted by parent(s)/legal guardian(s) at any time during the study) were reviewed
by an independent, central reviewer for unbiased assessment and confirmation of developmental milestone achievement.
Primary and secondary efficacy analyses were performed for participants with biallelic SMN1 deletions and three copies of SMN2
without the SMN2 gene modifier variant (c.859G>C), which is associated with a less severe clinical course, who were included in the
ITT population. Primary and secondary outcomes were compared with a cohort of population-matched patients from the PNCR
natural history data set (all patients with any type of SMA and three copies of SMN2; the SMN2 modifier mutation [c.859G>C] was
not assessed in the PNCR study cohort). For comparison, the number of patients who maintained the ability to thrive and/or were
independent of ventilator support at 18 months of age in the PNCR database was essentially zero. Because of computational
considerations, the comparison was made to 0.1% in lieu of zero. This study was designed to have >90% power with α = 0.05 to
detect a significant difference in independent sitting using a two sample two-sided Fisher exact test based on a sample size of ≥12
patients into the ITT population as well as assumptions based on a matched PNCR data set and START study data. Formal testing for
the primary and secondary efficacy endpoints was performed using a hierarchical approach to protect against Type I error as follows.
First, the primary endpoint of independent standing was assessed. If the analysis of the primary endpoint was determined to be
statistically significant (P<0.05), then formal testing of the first secondary endpoint, independent walking, was conducted.
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